JNJ-64007957

Overview

JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.

SparkCures ID 279
Developed By Janssen Research & Development
Generic Name JNJ-64007957
Treatment Classifications
Treatment Targets

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.